重新审视酸在治疗性结肠炎中的作用
Moting Liu1,2, Yao Zhang3, Jia Liu4
1Laboratory of Anti-inflammation and Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Inflammatory bowel diseases
|January 11, 2024
概括
酸 (VA),一个短链脂肪酸 (SCFA),显示了性结肠炎 (UC) 的治疗潜力. 在UC模型中,VA治疗通过调节巨细胞激活和细胞因子产生来抑制炎症,这表明它可以作为一种新的UC治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 涉及炎症,上皮功能障碍,免疫反应和肠道失调的复杂相互作用.
- 酸 (VA),一个短链脂肪酸 (SCFA) 在UC病变发生过程中的作用尚未完全理解.
研究的目的:
- 研究VA在性结肠炎中的病理作用和潜在机制.
- 在UC模型中评估VA的治疗潜力.
主要方法:
- 在人类UC患者和小鼠结肠炎模型中分析SCFA水平.
- 在小鼠结肠炎模型和巨细胞采用转移实验中进行VA的干预.
- 评估巨细胞激活和炎症标志物,如介白素-6 (IL-6).
主要成果:
- 在UC患者和模型中观察到SCFA,包括VA的变化.
- VA水平与UC疾病严重程度,单细胞数量和IL-6水平有负相关性.
- 通过高调节GPR41/GPR43和调节IL-6的产生,VA治疗抑制了LPS激活的免疫细胞,并改善了DSS诱导的大肠炎.
结论:
- 在UC中,VA在调节巨细胞激活方面起着病理作用.
- VA显示出作为性结肠炎的有效治疗剂的潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
433
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
433
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
490
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
490
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
430
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430
Peptic Ulcer Disease IV: Management
94
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
94
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
441
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
441


